Clinical Research Directory
Browse clinical research sites, groups, and studies.
Investigation of Three Biomarkers for the Detection of Prostate Cancer
Sponsor: Medtechtomarket Consulting Ltd
Summary
GlycoScore Dx Limited, a diagnostics company based in the United Kingdom have identified three glycoproteins, that showed promise as biomarkers of prostate cancer in initial validation studies. The purpose of this study is to further evaluate the sensitivity and specificity of the GlycoScore biomarkers for the detection of clinically significant prostate cancer. Sensitivity and specificity will be determined for each marker, combinations of the three markers and combinations of the GlycoScore biomarkers with PSA (prostate specific antigen). The results from this study will be used to identify the most suitable biomarker/biomarkers for use in developing a GlycoScore test. This is a prospective, non-interventional study using venous blood samples taken from patients with suspected prostate cancer or on active surveillance, attending the hospital Urology department for a transperineal biopsy.
Official title: Evaluation of the Performance of the Glycoscore Biomarkers for the Detection of Clinically Significant Prostate Cancer
Key Details
Gender
MALE
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
137
Start Date
2025-01-07
Completion Date
2026-03-07
Last Updated
2025-01-17
Healthy Volunteers
No
Conditions
Interventions
Laboratory Biomarker Analysis: Enzyme-linked immunosorbent assay (ELISA)
Measurement of the plasma concentration of ST6GAL1, GCNT1 and GALNT7 biomarkers in patients suspected of having prostate cancer or on active surveillance
Locations (1)
Royal Liverpool University Hospital
Liverpool, United Kingdom